SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JULY 1, 2000

0R

[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM _____ TO _____.

COMMISSION FILE #0-4829-03

NABI _____

(Exact name of registrant as specified in its charter)

DELAWARE ----------

(State or other jurisdiction of incorporation or organization)

59-1212264 _ _ _ _ _ _ _ _ _ _ _ _ _ (I.R.S. Employer Identification No.)

33487 -----

(Zip Code)

5800 PARK OF COMMERCE BOULEVARD N.W., BOCA RATON, FL (Address of principal executive offices)

(Registrant's telephone number, including area code):

(561) 989-5800 -----

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.

YES [X] NO []

The number of shares outstanding of registrant's common stock at July 27, 2000 was 37,672,227 shares.

NABI

INDEX

PAGE

PART I. FINANCIAL INFORMATION

	ITEM 1. FINANCIAL STATEMENTS
	Consolidated Balance Sheets, July 1, 2000 and December 31, 1999
	Consolidated Statements of Operations for the three-month and six-month periods ended
	July 1, 2000 and June 30, 19994
	Consolidated Statements of Cash Flows for the six-month periods ended
	July 1, 2000 and June 30, 19995
	Notes to Consolidated Financial Statements6
	ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
PART	II. OTHER INFORMATION
	ITEM 1.LEGAL PROCEEDINGS.14ITEM 2.CHANGES IN SECURITIES.14ITEM 4.SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.15ITEM 6.EXHIBITS AND REPORTS ON FORM 8-K.15
	Exhibit 27 - Financial Data Schedule (for S.E.C. use only)17

NABI PART I FINANCIAL INFORMATION ITEM 1 FINANCIAL STATEMENTS

CONSOLIDATED BALANCE SHEETS

	(UNAUDITED) JULY 1,	DECEMBER 31,
IN THOUSANDS	2000	1999
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 1,586	\$ 806
Trade accounts receivable, net Inventories, net	32,109 33,425	34,019 35,932
Prepaid expenses and other assets	6,887	8,149
TOTAL CURRENT ASSETS	74,007	78,906
TOTAL CONCENT ASSETS	14,001	10,000
PROPERTY AND EQUIPMENT, NET	114,810	109,138
OTHER ASSETS:		
Goodwill, net	12,873	13,236
Intangible assets, net Other, net	5,631 7,097	6,028 7,256
TOTAL ASSETS	\$ 214, 418 =============	\$ 214,564 ===========
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Trade accounts payable	\$ 13,701	\$ 16,025
Accrued expenses	19,856	26,178
Notes payable	1,000	704
TOTAL CURRENT LIABILITIES	34,557	42,907
NOTES PAYABLE	113,574	112,294
OTHER	1,315	1,186
TOTAL LIABILITIES	149,446	156,387
STOCKHOLDERS' EQUITY: Convertible preferred stock, par value \$.10 per share: 5,000 shares authorized; no shares outstanding		
Common stock, par value \$.10 per share: 75,000 shares authorized;		
35,989 and 34,961 shares issued and outstanding, respectively	3,599	3,496
Capital in excess of par value Accumulated deficit	142,799 (81,426)	138,071 (83,390)
TOTAL STOCKHOLDERS' EQUITY	64,972	58,177
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 214,418 ============	\$ 214,564
		· -

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.

CONSOLIDATED STATEMENTS OF OPERATIONS

	(UNAUDITED) THREE MONTHS ENDED,		SIX MO	AUDITED) NTHS ENDED,
DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA		JUNE 30, 1999		
SALES	\$ 57,581	\$ 62,198	\$ 113,421	\$ 120,221
Costs and expenses: Costs of products sold Selling, general and administrative expense Research and development expense Royalty expense Other operating expense, principally freight and amortization	39,888 8,687 3,781 2,809 457	42,669 8,513 3,868 3,914 487	78,350 17,121 7,777 5,730 957	87,898 14,996 7,061 6,091 978
Operating income	1,959	2,747	3,486	3,197
Interest income Interest expense Other, net	10 (980) 3	54 (980) (13)	136 (2,005) 74	60 (2,291) (54)
Income before provision for income taxes and extraordinary gain	992	1,808	1,691	912
Provision for income taxes	(45)	(756)	(67)	(374)
Income before extraordinary gain	947	1,052	1,624	538
Extraordinary gain, net of income taxes of \$13	340		340	
Net income	\$ 1,287 =======	\$ 1,052 ======	\$ 1,964 ======	\$ 538 =======
Basic earnings per share: Income before extraordinary gain Extraordinary gain	\$ 0.03 0.01	\$ 0.03	\$0.05 0.01	\$ 0.02
Net income	\$ 0.04 ======	\$ 0.03 ======	\$ 0.06 ======	\$ 0.02 ======
Diluted earnings per share: Income before extraordinary gain Extraordinary gain	\$ 0.03 0.01	\$ 0.03	\$ 0.04 0.01	\$ 0.02
Net income	\$ 0.04 ======	\$ 0.03 ======	\$ 0.05 ======	\$ 0.02 ======
Basic weighted average shares outstanding	35,761 =======	34,926	35,573	34,916
Diluted weighted average shares outstanding	36,735 =======	35,242 ======	36,781	35,159 ======

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.

NABI

CONSOLIDATED STATEMENTS OF CASH FLOWS

Zash flow from operating activities: Net income \$ 1,964 \$ 538 Adjustments to reconcile net income to net cash provided \$ 0,967 \$ 1,964 \$ 538 Adjustments to reconcile net income to net cash provided \$ 0,968 \$ 0,272 \$ (10) Provision for doubtil accounts \$ 228 \$ (28) \$ (10) \$ 777 \$ 1,162 Defereid income taxes \$ 340 \$ 374 \$ 374 \$ 365 \$ 374 Extraordinary gain, net \$ (340) \$ 374 \$ 65 \$ 1,799 \$ (9,67) \$ 222 \$ 341 Decrease in noventories \$ 1,790 \$ (9,67) \$ (242) \$ 341 \$ 65 Decrease in noventories \$ 1,790 \$ (7)7 \$ 2,626 \$ 341 Increase in other assets \$ 1,765 \$ 1,743 \$ 16,316 Total adjustments \$ 1,774 \$ 16,364 \$ 777 \$ 16,854 Vet cash provided by operating activities \$ 3,787 \$ 16,9647 \$ 7,518 \$ 7,518 Vet cash used by investing activities: \$ 7,667 \$ 7,518 \$ 7,566 \$ 2,518 Borrowings (repayments) under line of credit, net \$ 3,760 <td< th=""><th></th><th>SIX MONT</th><th colspan="3">(UNAUDITED) SIX MONTHS ENDED,</th></td<>		SIX MONT	(UNAUDITED) SIX MONTHS ENDED,		
Net income\$ 1,964\$ 538Adjustments to reconcile net income to net cash provided5,9365,272by operating activities: Depreciation and amortization Provision for doubtful accounts5,9365,272provision for doubtful accounts Provision for slow moving or obsolete inventory 	DOLLARS IN THOUSANDS	JULY 1, 2000	JUNE 30, 1999		
Adjustments to reconcile net income to net cash provided5,0365,272by opertaing activities:5,0365,272provision for doubtful accounts(28)(10)provision for slow moving or obsolete inventory7171,162Deferred income taxes374Extraordinary gain, net(340)Other1465Change in assets and liabilities:1,7658,128Decrease in trade accounts receivable1,7658,128Decrease in inventories1,7658,128Decrease in inventories1,7658,128Decrease in accounts payable and accrued liabilities(87)(242)Decrease in accounts payable and accrued liabilities(87)(242)Decrease for minosting activitiesTotal adjustments1,74316,336Vet cash provided by operating activities2,538Capital expenditures(9,667)(9,804)Net cash used by investing activities:Proceeds from financing activities:Borrowings (regaments) under line of credit, net3,780(9,609)Proceeds from the exercise of stock options3,16620Net cash provided (used) by financing activitiesBorrowings (regaments) under line of period8061,015Cash and cash equivalents at end of period8061,015Cash and cash equivalents at end of period8061,015Cash and cash equivalents at end of perio	Cash flow from operating activities:				
Depreciation and amortization5,0865,272Provision for doubtful accounts(28)(10)Provision for slow moving or obsolete inventory7171,162Deferred income taxes374Extraordinary gain, net(340)Other1465Change in assets and liabilities:1,7658,128Decrease in trade accounts receivable1,7658,128Decrease in inventories1,762341Increase in other assets(67)(242)Decrease in accounts payable and accrued liabilities(8,386)(2,846)Total adjustmentsNet cash provided by operating activities:2,518Proceeds from sale of antibody centers2,518Capital expenditures(9,667)(9,904)Net cash used by investing activities:2,518Borrowings (repayments) under line of credit, net3,780(9,660)Repayments of term debt(167)Proceeds from the exercise of stock options3,16620Vet cash provided (used) by financing activitiesCash and cash equivalents at beginning of period8051,016Cash and cash equivalents at beginning of period8051,016Cash and cash equivalents at beginning of period51,258SupPLEMENTAL CASH FLOW INFORMATION:	Adjustments to reconcile net income to net cash provided	\$ 1,964	\$ 538		
Provision for doubtful accounts(28)(10)Provision for slow moving or obsolete inventory7171,162Deferred income taxes374Extraordinary gain, net1465Other1465Change in assets and liabilities:1465Decrease in trade accounts receivable1,7658,128Decrease in nethories1,7994,072Decrease in other assets1,262341Increase in accounts payable and accrued liabilities(87)(242)Decrease in accounts payable and accrued liabilities0,8366)(2,246)Total adjustments1,74316,316Total adjustments2,518Capital expenditures(9,667)(7,286)Cash flow from investing activities:2,518Proceeds from sale of antibody centers2,518Capital expenditures(9,667)(7,286)Cash flow from financing activities:Borrowings (repayments) under line of credit, net3,780(9,669)Repayments of term debt(167)Other debt(39)198Proceeds from the exercise of stock options3,16620Vet cash used by financing activitiesSupPLEMENTAL CASH FLOW INFORMATION:Uter cash and cash equivalents at hed of period\$ 1,566\$ 1,112SupPLEMENTAL CASH FLOW INFORMATION:Cash and cash equivalents at hed of period\$ 1,566\$ 1,211 <td>, i o</td> <td>5,036</td> <td>5,272</td>	, i o	5,036	5,272		
Deferred income taxes374Extraordinary gain, net(349)Other1465Change in assets and liabilities:Decrease in trade accounts receivable1,7658,128Decrease in inventories1,7604,072Decrease in inventories1,262341Increase in accounts payable and accrued liabilities(87)(242)Decrease in accounts payable and accrued liabilities(87)(242)Decrease in accounts payable and accrued liabilities3,760(2,846)Total adjustments1,74316,316Wet cash provided by operating activities:2,518Proceeds from sale of antibody centers2,518Capital expenditures(9,667)(7,286)Cash flow from financing activities:2,518Borrowings (repayments) under line of credit, net3,780(9,690)Repayments of term debt(167)Other debt(39)198Proceeds from the exercise of stock options3,16620Net cash provided (used) by financing activitiesSupPLEMENTAL CASH FLOW INFORMATION:SupPLEMENTAL CASH FLOW INFORMATION:Interest paid\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 1,566\$ 1,112SupPLEMENTAL CASH FLOW INFORMATION:Interest paid\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 1,566\$ 1	Provision for doubtful accounts				
Extraordinary gain, net (346) 0ther 14 65 Change in assets and liabilities: Decrease in trade accounts receivable 1,765 8,128 Decrease in inventories 1,760 4,672 Decrease in inventories 1,760 4,672 Decrease in nother assets 1,262 341 Increase in other assets (87) (242) Decrease in accounts payable and accrued liabilities (8,366) (2,846) Total adjustments 1,773 16,354 Vet cash provided by operating activities 3,767 16,654 Proceeds from sale of antibody centers					
Other1465Change in assets and liabilities: Decrease in trade accounts receivable Decrease in inventories1,7658,128Decrease in prepaid expenses and other assets1,7658,128Decrease in prepaid expenses and other assets1,262341Increase in other assets(87)(242)Decrease in accounts payable and accrued liabilities(8,386)(2,846)Total adjustments1,74316,6316Total adjustments1,74316,654Net cash provided by operating activities: Proceeds from sale of antibody centers Capital expenditures					
Change in assets and liabilities: Decrease in trade accounts receivable Decrease in inventories Decrease in inventories Decrease in inventories Decrease in neutories Decrease in neutories 1,765 1,262 341 Increase in other assets 1,262 341 Increase in other assets 1,262 341 Increase in other assets 1,262 341 1,265 3,780 9,690 1,969 1,968 1,969 1,968 1,969 1,968 1,969 1,968 1,969 1,968 1,969 1,968 1,968 1,969 1,968 1,968 1,969 1,968		()			
Decrease in trade accounts receivable1,7658,128Decrease in inventories1,7804,072Decrease in in prepaid expenses and other assets1,262341Increase in other assets(87)(242)Decrease in accounts payable and accrued liabilities(8,366)(2,246)Total adjustments1,74316,316Net cash provided by operating activities3,70716,654Total expenditures(9,667)(9,804)Capital expenditures(9,667)(7,286)Cash flow from investing activities:	other	14	65		
Decrease in trade accounts receivable1,7658,128Decrease in inventories1,7804,072Decrease in in prepaid expenses and other assets1,262341Increase in other assets(87)(242)Decrease in accounts payable and accrued liabilities(8,366)(2,246)Total adjustments1,74316,316Net cash provided by operating activities3,70716,654Total expenditures(9,667)(9,804)Capital expenditures(9,667)(7,286)Cash flow from investing activities:	Change in assets and liabilities:				
Decrease in inventories1,7904,072Decrease in propud expenses and other assets1,262341Increase in accounts payable and accrued liabilities(8,366)(2,242)Decrease in accounts payable and accrued liabilities(8,366)(2,646)Total adjustments1,74316,316Net cash provided by operating activities3,76716,854Proceeds from sale of antibody centers		1.765	8,128		
Decrease in prepaid expenses and other assets1,262341Increase in other assets(87)(242)Decrease in accounts payable and accrued liabilities(8,386)(2,646)Total adjustments1,74316,316Total adjustments3,76716,854Vet cash provided by operating activities:			,		
Increase in other assets [87] (242] Decrease in accounts payable and accrued liabilities (8,386) (2,846) Total adjustments 1,743 16,316 Total adjustments 3,707 16,854 Total adjustments 3,707 16,854 Total adjustments 3,707 16,854 Total adjustments 2,518 Capital expenditures (9,667) (9,804) Total adjusting activities (9,667) (7,286) Total adjustments 0,667) (7,286) Total adjustments 1,000 (9,690) Repayments of term debt (167) Other debt (39) 198 Proceeds from the exercise of stock options 3,166 20 Net cash equivalents at beginning of period 806 1,016 Cash and cash equivalents at beginning of period 806 1,016 Cash and cash equivalents at end of period 5,1586 \$ 1,112 SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid 5,2000					
Total adjustments1,74316,316Vet cash provided by operating activities3,70716,854Cash flow from investing activities: Proceeds from sale of antibody centers Capital expenditures-2,518Vet cash used by investing activities: Borrowings (repayments) under line of credit, net Repayments of term debt Other debt3,780(9,667)Vet cash provided (used) by financing activities: Borrowings (repayments) under line of credit, net Cash flow from the exercise of stock options3,780(9,690)Vet cash used duivalents3,780(9,690)Cash and cash equivalents6,740(9,472)Vet increase in cash and cash equivalents Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at beginning of period\$ 1,586\$ 1,112SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid\$ 4,231\$ 4,211Income taxes refunded(\$ 43)(\$ 111)Von-cash extinguishment of convertible subordinated debentures in exchange for common stock\$ 2,000			(242)		
Total adjustments1,74316,316Net cash provided by operating activities3,70716,854Proceeds from sale of antibody centers-2,518Capital expenditures(9,667)(9,804)Net cash used by investing activities(9,667)(7,286)Cash flow from financing activities:Borrowings (repayments) under line of credit, net Other debt3,780(9,690)Repayments of term debt(167)Other debt(39)198Proceeds from the exercise of stock options3,16620Net cash provided (used) by financing activities6,740(9,472)Net cash and cash equivalents78096Cash and cash equivalents at end of period8661,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid	Decrease in accounts payable and accrued liabilities	(8, 386)	(2,846)		
Net cash provided by operating activities 3,707 16,854 					
Net cash provided by operating activities3,70716,854Cash flow from investing activities: Proceeds from sale of antibody centers Capital expenditures-2,518Proceeds from sale of antibody centers Capital expenditures(9,667)(9,804)Vet cash used by investing activities(9,667)(7,286)Cash flow from financing activities: Borrowings (repayments) under line of credit, net Other debt Proceeds from the exercise of stock options3,780(9,690)Net cash provided (used) by financing activities(167)Net cash and cash equivalents Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents ta beginning of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$	Total adjustments				
Cash flow from investing activities: Proceeds from sale of antibody centers Capital expenditures2,518 (9,667)Vet cash used by investing activities(9,667)(9,804)Vet cash used by investing activities: Borrowings (repayments) under line of credit, net Repayments of term debt Other debt3,780(9,669)Proceeds from the exercise of stock options3,16620Vet cash provided (used) by financing activities: Borrowing activalents	let cash provided by operating activities	3,707	16,854		
Net cash used by investing activities(9,667)(7,286)Cash flow from financing activities:		(9,667)	(9,804)		
Cash flow from financing activities: Borrowings (repayments) under line of credit, net3,780 (167) (167)9,690) (167)Repayments of term debt Other debt Proceeds from the exercise of stock options(167) (39)198 198 20Vet cash provided (used) by financing activities6,740 (9,472)(9,472)Net cash and cash equivalents Cash and cash equivalents at beginning of period780 806 1,01696 1,016Cash and cash equivalents at end of period\$ 1,586 4,211 ====================================	Net cash used by investing activities	(9,667)	(7,286)		
Borrowings (repayments) under line of credit, net3,780(9,690)Repayments of term debt(167)Other debt(39)198Proceeds from the exercise of stock options3,16620Net cash provided (used) by financing activities6,740(9,472)Net cash provided (used) by financing of period8061,016Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112SUPPLEMENTAL CASH FLOW INFORMATION:	Cash flow from financing activities:				
Repayments of term debt(167)Other debt(39)198Proceeds from the exercise of stock options3,16620Net cash provided (used) by financing activities6,740(9,472)Net cash and cash equivalents78096Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112SUPPLEMENTAL CASH FLOW INFORMATION:		3,780	(9,690)		
Other debt(39)198Proceeds from the exercise of stock options3,16620Net cash provided (used) by financing activities6,740(9,472)Net increase in cash and cash equivalents78096Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 4,231\$ 4,211SUPPLEMENTAL CASH FLOW INFORMATION:\$ 4,231\$ 4,211Interest paid\$ 4,231\$ 4,211Income taxes refunded(\$ 43)(\$ 111)Von-cash extinguishment of convertible subordinated debentures in exchange for common stock\$ 2,000		,			
Net cash provided (used) by financing activities6,740(9,472)Net increase in cash and cash equivalents78096Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents\$ 4,231\$ 4,211Interest paid\$ 4,231\$ 4,211Income taxes refunded(\$ 43)(\$ 111)Non-cash extinguishment of convertible subordinated debentures in exchange for common stock\$ 2,000			198		
Net cash provided (used) by financing activities6,740(9,472)Net increase in cash and cash equivalents78096Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents at end of period\$ 4,231\$ 4,211Cash and cash equivalents\$ 4,231\$ 4,211Cash and cash equivalents\$ 4,231\$ 4,211Cash and cash equivalents\$ 43)(\$ 111)Cash and cash equivalent of convertible subordinated debentures in exchange for common stock\$ 2,000	Proceeds from the exercise of stock options				
Wet increase in cash and cash equivalents at beginning of period 780 96 Stash and cash equivalents at beginning of period 806 1,016 Cash and cash equivalents at end of period \$ 1,586 \$ 1,112 Cash and cash equivalents at end of period \$ 1,586 \$ 1,112 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalents at end of period \$ 4,231 \$ 4,211 Cash and cash equivalent at end of period \$ 43) (\$ 111) Cash at experiment of convertible subordinated debentures in exchange for common stock \$ 2,000	let cash provided (used) by financing activities				
Cash and cash equivalents at beginning of period8061,016Cash and cash equivalents at end of period\$ 1,586\$ 1,112Cash and cash equivalents at end of period\$ 1,586\$ 1,112SUPPLEMENTAL CASH FLOW INFORMATION:========Interest paid\$ 4,231\$ 4,211Income taxes refunded(\$ 43)(\$ 111)Von-cash extinguishment of convertible subordinated debentures in exchange for common stock\$ 2,000					
Cash and cash equivalents at end of period \$ 1,586 \$ 1,112 SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid \$ 4,231 \$ 4,211 ===================================	Vet increase in cash and cash equivalents	780	96		
Cash and cash equivalents at end of period\$ 1,586 =======\$ 1,112 ======SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid\$ 4,231 ======\$ 4,231 ======Income taxes refunded debentures in exchange for common stock\$ 2,000		806	,		
SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid \$ 4,231 \$ 4,211 ===================================	Sach and each equivalants at and of paried				
SUPPLEMENTAL CASH FLOW INFORMATION: Interest paid \$4,231 \$4,211 ======= (\$43) (\$111) ===== (\$43) (\$111) ===== = = Non-cash extinguishment of convertible subordinated debentures in exchange for common stock \$2,000	ash anu cash equivalents at enu or perioù				
Interest paid \$ 4,231 \$ 4,211 ===================================	SUPPLEMENTAL CASH FLOW INFORMATION.				
Income taxes refunded (\$ 43) (\$ 111) ==================================		\$ 4,231	\$ 4,211		
Non-cash extinguishment of convertible subordinated debentures in exchange for common stock \$ 2,000	and the second				
Non-cash extinguishment of convertible subordinated debentures in exchange for common stock \$ 2,000	Income taxes refunded				
debentures in exchange for common stock\$ 2,000	Non-cash extinguishment of convertible subordinated				
		\$ 2,000			
		=======	========		

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE FINANCIAL STATEMENTS.

5

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1. GENERAL

We are nearing completion of a multi-year transition from being a leading provider of antibody products to other pharmaceutical manufacturers to becoming a fully integrated biopharmaceutical company, developing, manufacturing and marketing our own products for the prevention and treatment of infectious diseases and immunological disorders. We have a portfolio of marketed products and significant research and development capabilities that are focused on the development and commercialization of products that prevent and treat infectious and autoimmune diseases. We currently have several clinical trials underway in these areas and have four marketed pharmaceutical products.

The consolidated financial statements include the accounts of Nabi and its subsidiaries. All significant intercompany accounts and transactions were eliminated during the consolidation. These statements should be read in conjunction with the consolidated financial statements and notes thereto included in Nabi's Annual Report to Stockholders for the year ended December 31, 1999.

In the opinion of management, the unaudited consolidated financial statements include all adjustments necessary to present fairly our consolidated financial position at July 1, 2000 and the consolidated results of its operations for the three and six month periods ended July 1, 2000 and June 30, 1999. The interim results of operations are not necessarily indicative of the results that may occur for the fiscal year.

NOTE 2. INVENTORIES

The components of inventories, stated at the lower of cost (FIFO) or market, are as follows:

DOLLARS IN THOUSANDS	JULY 1, 2000	DECEMBER 31, 1999
Finished goods, net Work in process, net Raw materials, net	\$30,049 1,088 2,288	\$32,779 451 2,702
TOTAL	\$33,425 =======	\$35,932 ======

NOTE 3. NON-RECURRING CHARGES

During the fourth quarter of 1998, we recorded a non-recurring charge that included \$13.2 million related to a strategic plan to sell or close certain antibody collection centers and actions to reduce pre-clinical product development activities at our Rockville, Maryland facility. During 1999, we reduced staff levels at our Rockville facility, closed or sold seven U.S. antibody collection centers out of the eight centers specified in the original plan, and transferred our four German antibody collection centers and related operations to a third party.

As of July 1, 2000, \$3 million of the remaining restructuring accrual primarily relates to non-cancelable lease obligations associated with the Rockville facility and \$0.9 million associated with unpaid severance benefits and other costs related to disposition of the remaining antibody collection center. Resolution of the contemplated actions relating to the remaining antibody collection center is expected to be completed by the end of the third quarter of 2000.

A summary of our restructuring activity for the first six months of 2000 and 1999 is presented below:

DOLLARS IN THOUSANDS

Balance at December 31, 1999 Activity during 2000:	\$4,083
Termination benefit payments Other	(57) (159)
BALANCE AT JULY 1, 2000	\$3,867 =======

DOLLARS IN THOUSANDS

		-
Balance at December 31, 1998	\$13,214	
Activity during 1999:		
Termination benefit payments	(585)	
Non-cash write-downs of fixed and intangible assets	(4,295)	
Non-cancelable lease obligation payments		
and other cash outflows	(145)	
BALANCE AT JUNE 30, 1999	\$8,189	

NOTE 4. EARNINGS PER SHARE

The following is a reconciliation between basic and diluted earnings per share for the three and six-month periods ended July 1, 2000 and June 30, 1999:

	TH	IREE MONTHS ENDED,		S	IX MONTHS ENDED,	
(IN THOUSANDS, EXCEPT PER SHARE DATA)	BASIC EPS	EFFECT OF DILUTIVE SECURITIES; STOCK OPTIONS	DILUTED EPS	BASIC EPS	EFFECT OF DILUTIVE SECURITIES; STOCK OPTIONS	DILUTED EPS
,						
July 1, 2000						
Net income (loss)	\$ 1,287		\$ 1,287	\$ 1,964		\$ 1,964
Shares	35,761	974	36,735	35,573	1,208	36,781
Per share	\$ 0.04		\$ 0.04	\$ 0.06		\$ 0.05
June 30, 1999						
Net income (loss)	\$ 1,052		\$ 1,052	\$ 538		\$ 538
Shares	34,926	316	35,242	34,916	243	35,159
Per share	\$ 0.03		\$ 0.03	\$ 0.02		\$ 0.02
	======	====	=======	======	=======	=======

NOTE 5. COMPREHENSIVE INCOME

The components of comprehensive income for the three and six months ended July 1, 2000 and June 30, 1999 are as follows:

	THREE MON	THREE MONTHS ENDED,		HS ENDED,
DOLLARS IN THOUSANDS	JULY 1, 2000	JUNE 30, 1999	JULY 1, 2000	JUNE 30, 1999
Net income Foreign currency translation	\$1,287	\$1,052	\$1,964	\$ 538
loss		(155)		(297)
COMPREHENSIVE INCOME	\$1,287 ======	\$ 897 ======	\$1,964 ======	\$ 241 =====

NOTE 6. INDUSTRY SEGMENT INFORMATION

The following table presents information related to our two operating business segments for the three and six-month periods ended July 1, 2000 and June 30, 1999:

	THREE MON	THS ENDED,	SIX MONTH	IS ENDED,
DOLLARS IN THOUSANDS	JULY 1, 2000	JUNE 30, 1999	JULY 1, 2000	JUNE 30, 1999
Sales				
Antibody products	\$39,800	\$43,988	\$79,419	\$90,469
Pharmaceutical products	17,781	18,210	34,002	29,752
TOTAL	\$57,581	\$62,198	\$113,421	\$120,221
	======	======	=======	=======
Operating income (loss)				
Antibody products	\$(1,869)	\$1,504	\$(2,267)	\$2,220
Pharmaceutical products	3,828	1,243	5,753	977
TOTAL	\$1,959	\$2,747	\$3,486	\$3,197
	======	=======	=======	=======

The following summary reconciles reportable segment operating profit to income before provision for income taxes and extraordinary gain:

	THREE MON	THS ENDED,	SIX MONTH	IS ENDED,
DOLLARS IN THOUSANDS	JULY 1, 2000	JUNE 30, 1999	JULY 1, 2000	JUNE 30, 1999
INCOME BEFORE PROVISION FOR INCOME TAXES AND EXTRAORDINARY GAIN: Reportable segment operating income Unallocated interest expense Unallocated other income and expense, net	\$1,959 (980) 13	\$2,747 (980) 41	\$ 3,486 (2,005) 210	\$ 3,197 (2,291) 6
Consolidated income before provision for income taxes and extraordinary gain	\$ 992 ======	\$1,808 ======	\$ 1,691 =======	\$ 912 =======

NOTE 7. NOTES PAYABLE

During January 1996, we issued \$80.5 million of 6.5% Convertible Subordinated Notes due February 1, 2003 (the "Notes") in a private placement. The Notes are convertible into common stock at a conversion price of \$14 per share at any time and may be redeemed for cash at our option without premium. During June 2000, we accepted an offer and agreed to exchange an aggregate of 241,795 shares of our common stock for \$2 million of the Notes which were subsequently extinguished, resulting in an extraordinary gain of \$0.3 million, net of taxes, which is included in the results for the second quarter and six-month period ended July 1, 2000.

NOTE 8. SUBSEQUENT EVENT

On July 11, 2000, we completed a private placement of 1,666,667 shares of common stock to a group of institutional investors and realized net proceeds of approximately \$9.3 million. Proceeds from the equity private placement were used to reduce borrowings and increase availability under our existing bank line of credit. In connection with the offering, we issued five-year warrants to purchase 133,333 shares of common stock at an exercise price of \$7.50 per share to the placement agent.

NOTE 9. NEW ACCOUNTING PRONOUNCEMENTS

In December 1999, the Securities and Exchange Commission ("SEC") issued Staff Accounting Bulletin ("SAB") No. 101. SAB 101 summarizes certain of the SEC's views in applying general accepted accounting principles to certain revenue transactions in financial statements. Implementation of the SAB is required in the fourth quarter of 2000. We are currently assessing the impact, if any, and do not currently anticipate that SAB 101 will have a material effect on our financial position and results of operations.

NOTE 10. RECLASSIFICATIONS

Certain items in the consolidated financial statements for the 1999 period have been reclassified for comparative purposes.

ITEM 2

10

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a discussion and analysis of the major factors contributing to our financial condition and results of operations for the three and six-month periods ended July 1, 2000 and June 30, 1999. The discussion and analysis should be read in conjunction with the condensed consolidated financial statements and notes thereto. All dollar amounts are expressed in thousands, except per share amounts.

RESULTS OF OPERATIONS

The following table sets forth our results of operations expressed as a percentage of sales:

	THREE MONTHS ENDED,		SIX MONTHS ENDED,	
		JUNE 30, 1999	JULY 1, 2000	JUNE 30, 1999
Sales	100.0 %	100.0 %	100.0 %	100.0 %
Costs of products sold	69.3 %	68.6 %	69.1 %	73.1 %
Gross profit margin	30.7 %	31.4 %	30.9 %	26.9 %
Selling, general and administrative expense	15.1 %	13.7 %	15.1 %	12.5 %
Research and development expense	6.5 %	6.2 %	6.9 %	5.9 %
Royalty expense	4.9 %	6.3 %	5.0 %	5.1 %
Other operating expense, principally				
freight and amortization	0.8 %	0.8 %	0.8 %	0.7 %
Operating income	3.4 %	4.4 %	3.1 %	2.7 %
Interest income	0.0 %	0.1 %	0.0 %	0.0 %
Interest expense	(1.7)%	(1.6)%	(1.8)%	(1.9)%
Other, net	0.0 %	(0.0)%	0.2 %	(0.0)%
Income before provision for income taxes				
and extraordinary gain	1.7 %	2.9 %	1.5 %	0.8 %
Provision for income taxes	(0.1)%	(1.2)%	(0.1)%	(0.3)%
Income before extraordinary gain	1.6 %	1.7 %	1.4 %	0.5 %
Extraordinary gain, net	0.6 %	%	0.3 %	%
Net income	2.2 %	1.7 %	1.7 %	0.5 %

Information concerning sales by operating segments for the respective periods, is set forth in the following table:

	THREE MONTHS ENDED,				
SEGMENT	JULY 1, 2000		JUNE 30, 1999		
Pharmaceutical products Antibody products:	\$17,781	30.9%	\$18,210	29.3%	
- Non-specific antibodies	24,180	42.0	29,868	48.0	
- Specialty antibodies	15,620	27.1	14,120	22.7	
	39,800	69.1	43,988	70.7	
TOTAL	\$57,581 ======	100.0% =====	\$62,198 ======	100.0% =====	

SIX MONTHS ENDED, JULY 1, 2000 -----SEGMENT JUNE 30, 1999 ------ - - - - -Pharmaceutical products \$34.002 30.0% \$29,752 24.8% Antibody products: - Non-specific antibodies 49,590 43.7 61,962 51.5 - Specialty antibodies 29,829 26.3 28,507 23.7 79,419 70.0 90,469 75.2 TOTAL \$113,421 100.0% \$120,221 100.0% =====

THREE MONTHS ENDED JULY 1, 2000 AND JUNE 30, 1999

OVERVIEW. Our business strategy is to shift the mix of Nabi's sales from low-margin non-specific antibody products to higher margin specialty antibody and pharmaceutical products. Earnings from operations will be used to support our investment in the development of our product pipeline and manufacturing capacity.

SALES. Revenues from pharmaceutical products during the second quarter of 2000 were led by Nabi-HB(TM) [Hepatitis B Immune Globulin (Human)], which increased more than 40% from the second quarter of 1999, while total pharmaceutical revenues were essentially unchanged from the comparable prior year period. In the second quarter of 1999, pharmaceutical revenues benefited from the initial launch of Aloprim(TM) [Allopurinol Sodium for Injection]. Sales of WinRho SDF(R) [Rho(D) Immune Globulin (Human)] in the second quarter of 2000 were lower than the comparable period in 1999 based on ordering patterns from distributors and wholesalers.

Total revenues for the second quarter of 2000 were 7% below 1999, primarily due to a decrease in non-specific antibody product sales. This decrease was the result of our strategic decision to exit unprofitable operations through the sale, transfer or closure of 11 antibody collection centers in the U.S. and Germany during 1999, and our continuing emphasis on increasing production of higher margin specialty antibody products in 2000. The decrease in sales of non-specific antibodies was partially offset by increased specialty antibodies revenues in the second quarter of 2000. The overall increase in specialty antibody revenues in the second quarter of 2000 reflected higher sales of anti-rabies, anti-D and anti-CMV antibody products, and increased revenues from laboratory testing services, partially offset by a decrease in anti-Hbs sales.

GROSS PROFIT MARGIN. Gross profit and related margin for the second quarter of 2000 was \$17.7 million, or 31% of sales, compared to \$19.5 million, or 31% of sales in the second quarter of 1999. The decrease was primarily due to lower margins from antibody product sales, reflecting higher costs for antibody production, including costs to attract and retain donors and one-time costs for the implementation of a new donor management system. In addition, antibody margins were adversely affected by a decrease in high-margin anti-Hbs sales in 2000. The decrease in antibody margins was partially offset by increased margins from pharmaceutical revenues, including a benefit from a non-performance penalty payment due as a result of contractual delivery shortfalls by the supplier of Autoplex(R) T [Anti-Inhibitor Coagulant Complex, Heat Treated].

SELLING, GENERAL AND ADMINISTRATIVE EXPENSE. Selling, general and administrative expense was \$8.7 million, or 15% of sales, for the second quarter of 2000 compared to \$8.5 million, or 14% of sales, in the second quarter of 1999. The slight increase on a net basis is being driven by a 17% increase in advertising, marketing and expansion of our pharmaceutical sales force in order to support our continued growth in the pharmaceutical business for the remainder of 2000.

RESEARCH AND DEVELOPMENT EXPENSE. Research and development expense was \$3.8 million, or 7% of revenues in the second quarter of 2000 as compared to \$3.9 million, or 6% of revenues, in the second quarter of 1999. Overall, research and development expense in the second quarter of 2000 reflected continued support

for the Nabi(R)StaphVAX(R) (Staphylococcus aureus Type 5 and Type 8 Capsular Polysaccharide Conjugate Vaccine) pivotal Phase III clinical trial. Data collection was completed for the trial in the second quarter of 2000 and we are in the process of compiling the results which are anticipated to be announced around the end of the third quarter of 2000.

ROYALTY EXPENSE. Royalty expense was \$2.8 million, or 16% of pharmaceutical sales, in the second quarter of 2000, compared to \$3.9 million, or 21% of pharmaceutical sales, in the second quarter of 1999, reflecting the impact of the higher mix of Nabi-HB sales in the second quarter of 2000. Royalties to be paid on Nabi-HB in 2000 were capped under an agreement completed in the third quarter of 1999.

INTEREST EXPENSE. Interest expense was \$1 million, or 2% of revenues for the second quarter of 2000 and 1999. Although average bank borrowings were higher during the second quarter of 2000, interest expense did not increase because of the higher amounts of interest capitalized in the period. Capitalized interest relating primarily to construction of our biopharmaceutical facility in Boca Raton, Florida was approximately \$1.4 million and \$1.2 million for the quarters ending July 1, 2000 and June 30, 1999, respectively.

OTHER FACTORS. Provision for income taxes was \$45,000, recorded at an effective rate of 5%, in the second quarter of 2000 compared to \$756,000, or an effective rate of 42%, in the second quarter of 1999. The 5% effective tax rate in the second quarter of 2000 differs from the statutory rate of 35% due to our expectation of realizing a current year benefit from the use of a portion of our net operating loss carryforwards from prior years.

EXTRAORDINARY GAIN. During the second quarter of 2000, we exchanged an aggregate of 241,795 shares of our common stock for an aggregate of \$2 million of our 6.5% Convertible Subordinated Notes due 2003. The subsequent extinguishment of the Notes resulted in an extraordinary gain of \$0.3 million, net of taxes, that is included in the results for the second quarter ended July 1, 2000.

SIX MONTHS ENDED JULY 1, 2000 AND JUNE 30, 1999

SALES. Pharmaceutical product revenues increased in the six months of 2000 by approximately 14% from the comparable 1999 period. Revenues of Nabi-HB were higher based on a full six months of revenues in 2000, as compared to 1999 revenues which followed approval of the product by the FDA in late March, 1999. In addition, sales of WinRho SDF were higher in 2000 as compared to 1999 due to increased distributor demand. Sales of Aloprim in the first half of 1999 had benefited from the initial launch of the product in June 1999.

Overall revenues for the first half of 2000 decreased 6% from the same period in 1999, primarily due to the decrease in non-specific antibody sales. This decrease was the result of our strategic decision to exit unprofitable operations through the sale, transfer or closure of 11 antibody collection centers in the U.S. and Germany during 1999, and our continuing emphasis on increasing production of higher margin specialty antibody products in 2000. The decrease in sales of non-specific antibodies was partially offset by increased specialty antibodies revenues in the first half of 2000. The overall increase in specialty antibodies revenues in the first half of 2000 reflected increased revenues from laboratory testing services, and higher sales of anti-CMV and rabies antibody products, partially offset by a decrease in anti-Hbs antibody sales.

GROSS PROFIT MARGIN. Gross profit and related margin for the first half of 2000 was \$35.1 million, or 31% of sales, compared to \$32.3 million, or 27% of sales, in the first half of 1999. The increase reflects the benefit from non-performance penalty payments due as a result of contractual delivery shortfalls by the supplier of Autoplex T during the first six months of 2000 and our success in shifting the sales mix toward higher-margin pharmaceutical products.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSE. Selling, general and administrative expense was \$17.1 million, or 15% of sales, for the first half of 2000 compared

to \$15 million, or 13% of sales, in the first half of 1999. The increase is primarily attributable to higher advertising, marketing and sales force expenses associated with increasing pharmaceutical product sales.

RESEARCH AND DEVELOPMENT EXPENSE. Research and development expense was \$7.8 million, or 7% of sales, for the first half of 2000, compared to \$7.1 million, or 6% of sales, in the first half of 1999. The increase is primarily due to additional expenditures associated with the development and Phase IV clinical trials of Hepatitis B immune globulin (Human) for post-exposure prophylaxis of hepatitis B virus ("HBV") and the advancement of clinical trials to prevent the reinfection of transplanted livers in HBV positive patients. In addition, we incurred increased costs related to the ongoing Phase IV clinical trials for WinRho SDF during the six months of 2000. Overall, research and development expense in 2000 reflected continued support for Nabi StaphVAX pivotal Phase III clinical trial. Data collection was completed for the trial in the second quarter of 2000 and we are in the process of compiling the results which are anticipated to be announced around the end of the third quarter of 2000.

ROYALTY EXPENSE. Royalty expense for the first half of 2000 was \$5.7 million, or 17% of pharmaceutical sales, compared to \$6.1 million, or 21% of pharmaceutical sales, in the first half of 1999. Royalty expense decreased due to an agreement in the third quarter of 1999 limiting the amount of royalties to be paid on sales of Nabi-HB.

INTEREST EXPENSE. Interest expense for the first half of 2000 was \$2.0 million, or 2% of sales, compared to \$2.3 million, or 2% of sales, in the first half of 1999. The decrease is primarily attributable to higher amounts of interest capitalized during 2000. Capitalized interest relating primarily to construction of Nabi's biopharmaceutical manufacturing facility in Boca Raton, Florida was approximately \$2.7 million and \$2.3 million for the six months ending July 1, 2000 and June 30, 1999, respectively.

OTHER FACTORS. Provision for income taxes was \$67,000 or an effective rate of 4%, in the first half of 2000 compared to \$374,000, or an effective rate of 41%, in the first half of 1999. The 4% effective tax rate in the first half of 2000 differs from the statutory rate of 35% due to our expectation of realizing a current year benefit from the use of a portion of our net operating loss carryforwards from prior years.

EXTRAORDINARY GAIN. During the second quarter of 2000, we exchanged an aggregate of 241,795 shares of our common stock for an aggregate of \$2 million of its 6.5% Convertible Subordinated Notes due 2003. The subsequent extinguishment of the Notes resulted in an extraordinary gain of \$0.3 million, net of taxes, that is included in the results for the six months ended July 1, 2000.

LIQUIDITY AND CAPITAL RESOURCES

At July 1, 2000, our credit agreement provided for a revolving credit facility of up to \$45 million subject to certain borrowing base restrictions, and a \$4.8 million term loan. The credit agreement matures in September 2002. Borrowings under the agreement totaled \$36.1 million at July 1, 2000 as compared to \$32.5 million at December 31, 1999, and additional availability was approximately \$7.8 million at July 1, 2000. The credit agreement is secured by substantially all of our assets, requires the maintenance of certain financial covenants and prohibits the payment of dividends.

As of July 1, 2000, our current assets exceeded current liabilities by \$39.5 million as compared to a net working capital position of \$36 million at December 31, 1999. Cash and cash equivalents at July 1, 2000 were \$1.6 million compared to \$0.8 million at December 31, 1999. Cash provided from operations decreased by \$13.1 million in the six months of 2000 as compared to 1999. During 1999, we increased cash flow from operations by significantly reducing trade receivables and inventories. In 2000, we continued our focus on reducing our trade receivables and inventories while significantly reducing trade payables and accrued liabilities. In addition, we realized \$3.2 million of proceeds from the exercise of stock options. The primary uses of cash during the six months ended July 1, 2000 were capital expenditures and reduction of trade payables and accrued liabilities. Subsequent to the end of the second quarter, we raised \$10 million through a private placement of our common stock with a group of institutional investors improving our overall financial position. Proceeds from this equity private placement were used to reduce borrowings and increase availability under our existing bank line of credit.

Projected capital expenditures for the remainder of 2000 include costs associated with the Boca Raton manufacturing facility, including capitalized interest, the development of information systems and related expenditures, and antibody collection center renovations. During the second quarter of 2000, we finalized agreements with Collaborative BioAlliance, Inc. ("CBA") for the contract production and supply of Nabi StaphVAX at CBA's biomanufacturing facility in Rhode Island and began the investment in its development. We believe that cash flow from operations and our available bank credit facilities will be sufficient to meet our anticipated cash requirements for the remainder of 2000. We are also in the process of seeking additional cash to fund the development of our pharmaceutical product pipeline from strategic alliances and may seek additional funding from new or existing credit facilities and equity placements.

FACTORS TO BE CONSIDERED

The parts of this Quarterly Report on Form 10-Q captioned "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Legal Proceedings" contain certain forward-looking statements which involve risks and uncertainties. Readers should refer to a discussion under "Factors to be Considered" contained in our Annual Report on Form 10-K for the year ended December 31, 1999 concerning certain factors that could cause our actual results to differ materially from the results anticipated in such forward-looking statements. Said discussion is hereby incorporated by reference into this Quarterly Report.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are a party to litigation in the ordinary course of business. In addition, we are a co-defendant with various other parties in one suit filed in the U.S. by, or on behalf of, individuals who claim to have been infected with HIV as a result of either using HIV-contaminated products made by the defendants other than Nabi or having familial relations with those so infected. The claims made against us are based on negligence and strict liability. Several similar suits previously pending against us, including a purported class action, have been dismissed. We do not believe that any such litigation will have a material adverse effect on our business, financial position or results of operations.

ITEM 2. CHANGES IN SECURITIES

During June 2000, we issued 241,795 shares of our common stock in exchange for an aggregate of 2 million of our 6.5% Convertible Subordinated Notes due 2003. These shares were issued in an exempt transaction pursuant to Rule 3(a)(9) of the Securities Act of 1933 relating to an exchange of a security by us with our existing security holders where no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange. There was no underwriter.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The following matters were approved at our annual stockholders' meeting, which was held on May 26, 2000:

a) Election of the following to the Board of Directors:

		VOTES		
	FOR	WITHHELD		
David L. Castaldi George W. Ebright David J. Gury Richard A. Harvey, Ju Linda Jenckes David A. Thompson	32, 393, 720 32, 351, 133 32, 337, 018 7. 32, 391, 262 32, 388, 820 32, 393, 070	233,247 275,834 289,949 235,705 238,147 233,897		

b) Approval of the 2000 Equity Incentive Plan:

VOTES						
FOR	AGAINST	ABSTAIN	BROKER NON-VOTES			
14,606,462	1,722,095	96,291	16,202,119			

c) Approval of the 2000 Employee Stock Purchase Plan:

VOTES					
FOR	AGAINST	ABSTAIN	BROKER NON-VOTES		
15,849,879	486,297	88,972	16,202,119		

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

a) None

b) Reports on Form 8-K:

None

NABI SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


NABI

Date: August 1, 2000

By: /s/ THOMAS MCLAIN THOMAS H. MCLAIN Senior Vice President, Corporate Services and Chief Financial Officer

THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONSOLIDATED BALANCE SHEET (UNAUDITED) AT JULY 1, 2000 AND THE CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED) FOR THE SIX MONTHS ENDED JULY 1, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.

1,000 US DOLLARS



Receivables, inventory and PP&E represent net amounts
 Loss provision included in other expenses